CN101926955B - Medicament for treating stomach illness - Google Patents
Medicament for treating stomach illness Download PDFInfo
- Publication number
- CN101926955B CN101926955B CN2010102627438A CN201010262743A CN101926955B CN 101926955 B CN101926955 B CN 101926955B CN 2010102627438 A CN2010102627438 A CN 2010102627438A CN 201010262743 A CN201010262743 A CN 201010262743A CN 101926955 B CN101926955 B CN 101926955B
- Authority
- CN
- China
- Prior art keywords
- grams
- fine powder
- rhizoma
- medicament
- subsequent use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention relates to a medicament for treating stomach illness. Active ingredients of the medicament consist of the following components by weight: 155 to 165 grams of golden thread, 155 to 165 grams of cuttlebone, 75 to 85 grams of thunberg fritillary bulb, 75 to 85 grams of prepared rhizoma corydalis, 62 to 66 grams of salvia miltiorrhiza bunge, 38 to 42 grams of officinal magnolia bark, 38 to 42 grams of amomum fruit, 75 to 85 grams of bletilla and 38 to 42 grams of rhubarb. The medicament is prepared by the following steps of: grinding the cuttlebone and the bletilla into fine powder; extracting volatile oil from the amomum fruit and the magnolia bark; distilling to prepare aqueous solution; preparing the golden thread, the salvia miltiorrhiza bunge, the prepared rhizoma corydalis, the thunberg fritillary bulb and the rhubarb into water extraction solution; combining the water extraction solution with the aqueous solution; decompressing and concentrating the mixed solution until the relative density of the mixed solution is between 1.25 and 1.30; uniformly mixing the mixed solution and the fine powder to prepare thick paste; drying the thick paste at a low temperature; preparing the dried thick paste into fine powder; uniformly mixing the fine powder and the volatile oil; and encapsulating the mixture to obtain capsules. The medicament has the advantages of capability of effectively treating chronic gastritis and peptic ulcer, determined curative effect, good clinical treatment effect and total effective rate of up to 99.2 percent.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine, particularly a kind of medicine of treating gastropathy.It is a kind of compound Chinese patent medicine, is used to treat chronic gastritis, peptic ulcer.
Background technology
Chronic gastritis, peptic ulcer are a kind of digestive tract commonly encountered diseases, and its clinical manifestation is mainly the glutted discomfort of upper abdomen, irregularities stomachache, belch, pantothenic acid, feel sick, vomiting etc.This kind course of disease is longer, and symptom is complicated, and sickness rate and relapse rate are higher, and people's life is caused tangible influence.At present, the medicine that is used to treat chronic gastritis and peptic ulcer is a lot, like gastro-kinetic agent, gastric mucosa protectant, bismuth and various compound recipe Western medicine prepn and Chinese patent medicine SANJIU WEITAI, WENWEISHU, YANGWEISHU, relaxing liver and strengthening stomach ball etc.; Though these medicines are having certain curative effect aspect the treatment gastropathy; But these medicines have toxic and side effects in various degree to liver, renal function, and; Cost an arm and a leg, thus influence and limited the clinical application range and the therapeutic effect of these medicines.
Summary of the invention
The object of the present invention is to provide a kind of medicine of treating gastropathy; It can overcome the deficiency of prior art; This medicine has the function of heat clearing and damp drying, blood circulation promoting and blood stasis dispelling and stomach and alleviating pain, dephlogistication and promoting nuscle growth; And liver, renal function are had no side effect,, can treat chronic gastritis and peptic ulcer effectively the gastrointestinal tract vacuum response.
Active component of the present invention is made up of following component and weight proportion thereof.Its concrete component is calculated by weight as follows:
Rhizoma Coptidis 155-165g, Os Sepiae 155-165g, Bulbus Fritillariae Thunbergii 75-85g, system Rhizoma Corydalis 75-85g, Radix Salviae Miltiorrhizae 62-66g, Cortex Magnoliae Officinalis 38-42g, Fructus Amomi 38-42g, Pseudobulbus Bletillae (Rhizoma Bletillae) 75-85g, Radix Et Rhizoma Rhei 38-42g.
Press formula ratio weighting raw materials material, Os Sepiae, the Pseudobulbus Bletillae (Rhizoma Bletillae) pulverized process fine powder, cross medical sieve, subsequent use; Get Fructus Amomi, Cortex Magnoliae Officinalis extraction volatile oil, redistillation makes aqueous solution device collection in addition, and is subsequent use; Adopt water extraction process to process water extraction solution Rhizoma Coptidis, Radix Salviae Miltiorrhizae, system Rhizoma Corydalis, Bulbus Fritillariae Thunbergii, Radix Et Rhizoma Rhei, then merge with above-mentioned subsequent use aqueous solution, reducing pressure, be concentrated into relative density is 1.25-1.30; With above-mentioned subsequent use fine powder mix homogeneously, process thick paste again, cold drying is again pulverized and is processed fine powder, crosses medical sieve, with above-mentioned subsequent use volatile oil mixing, incapsulates again, promptly can be made into capsule.
Chronic gastritis, peptic ulcer are a kind of digestive tract commonly encountered diseases, and its course of disease is longer, and etiology and pathogenesis is complicated.This disease mainly is owing to all evil equivalent damage taste of eating and drinking without temperance, disorder of emotion and cold and heat, spleen insufficiency, endogenous damp formation, disorder of stomach-QI, depression and stagnation of QI; The course of disease with the passing of time, then damp-stagnancy heat-transformation, thermal burn stomach network, hollow heart is an infections, is the main cause of primary disease.Therefore, heat-clearing and toxic substances removing, dephlogistication and promoting nuscle growth, blood circulation promoting and blood stasis dispelling, invigorating the spleen and regulating the stomach are the basic rule of treatment of primary disease.
But Rhizoma Coptidis heat clearing and damp drying, consolidating YIN in the present invention's prescription, Os Sepiae antacid, pain relieving, convergence, two medicines are collaborative, are monarch drug; Radix Salviae Miltiorrhizae, Rhizoma Corydalis can blood circulation promoting and blood stasis dispelling, improve the local mucous membrane microcirculation, suppress inflammatory reaction, help tissue repair and regeneration, impel ulcer healing, are ministerial drug; Assistant is held back skin ulcer and is closed up with Pseudobulbus Bletillae (Rhizoma Bletillae) putrefaction-removing granulation-promoting; With Fructus Amomi, Cortex Magnoliae Officinalis invigorating the spleen and regulating the stomach, circulation of qi promoting removing dampness, relieving distension completely for making; Radix Et Rhizoma Rhei is good at soup and is washed gastrointestinal, stagnant, by rotten collateral dredging, share with Rhizoma Coptidis, and HP is had stronger killing action, helps ulcer healing, reduces relapse rate.Above-mentioned all medicines share, and have the effect of heat clearing and damp drying, blood circulation promoting and blood stasis dispelling and stomach and alleviating pain, dephlogistication and promoting nuscle growth.
The present invention adopts technique scheme; From finding out this stability of drug, pharmacodynamics, toxicology test and clinical observation on the therapeutic effect, pharmaceutical properties of the present invention is stable, has the effect of antiinflammatory, analgesia, antacid and promotion ulcer healing; There is not tangible toxic action again; And, liver, renal function are also had no side effect, non-stimulated to gastrointestinal tract again.Clinical practice is safe and reliable, and is easy to carry again, and the side of taking makes.For treatment chronic gastritis and peptic ulcer determined curative effect, can improve clinical symptoms rapidly, late result is good, and relapse rate is low, and clinical therapeutic efficacy is preferably arranged, and its cure rate is 67.2%, and obvious effective rate is 26.4%, and total effective rate reaches 99.2%.
Description of drawings
Accompanying drawing is a kind of process chart of treating the medicine of gastropathy.
The specific embodiment
Describe the specific embodiment of the present invention in detail below in conjunction with embodiment.
Embodiment 1
Take by weighing raw material by prescription: Rhizoma Coptidis 160g, Os Sepiae 160g, Bulbus Fritillariae Thunbergii 80g, system Rhizoma Corydalis 80g, Radix Salviae Miltiorrhizae 64g, Cortex Magnoliae Officinalis 40g, Fructus Amomi 40g, Pseudobulbus Bletillae (Rhizoma Bletillae) 80g, Radix Et Rhizoma Rhei 40g.
Earlier the above-mentioned Os Sepiae that takes by weighing and the Pseudobulbus Bletillae (Rhizoma Bletillae) are pulverized, crossed medical sieve, process fine powder, subsequent use; Get the above-mentioned Fructus Amomi that takes by weighing, Cortex Magnoliae Officinalis extraction volatile oil, then be distilled into aqueous solution, subsequent use, and medicinal residues emit; With the above-mentioned Rhizoma Coptidis that takes by weighing, Bulbus Fritillariae Thunbergii, system Rhizoma Corydalis, Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, place and dissolve device, add the water that above-mentioned raw materials weighs 10 times of amounts, warm macerating 0.5h; Decoct 2.5h again, take out the water that decocting liquid adds 10 times of amounts again, decoct 1.5h for the second time; 2 decocting liquids are merged, filter, medicinal residues emit; And the aqueous solution after filtrating and the above-mentioned subsequent use distillation merges, and through being evaporated to the medicinal liquid that relative density is 1.25-1.30, the detection of this relative density is under temperature is 60 ℃ condition, to carry out.Add above-mentioned subsequent use fine powder again, mix homogeneously is processed thick paste, moves in the exsiccator after the cold drying, is ground into fine powder again, crosses medical sieve, adds said extracted volatile oil, and mix homogeneously in incapsulating, is processed 1000 seed lac wafers, is packaged into finished product.Every 0.3g is equivalent to crude drug 0.7g.Instructions of taking: oral, each 5, every day 3 times.Medicine of the present invention is processed capsule, and its content medicine is the powder of brown white, and feeble QI is fragrant, bitter in the mouth.
Above-mentioned all raw medicinal materials are all on sale on market, are prone to purchase.
Embodiment 2
Take by weighing raw material by prescription: Rhizoma Coptidis 155g, Os Sepiae 160g, Bulbus Fritillariae Thunbergii 85g, system Rhizoma Corydalis 85g, Radix Salviae Miltiorrhizae 66g, Cortex Magnoliae Officinalis 38g, Fructus Amomi 42g, Pseudobulbus Bletillae (Rhizoma Bletillae) 75g, Radix Et Rhizoma Rhei 42g.Other is all with embodiment 1.
Embodiment 3
Take by weighing raw material by prescription: Rhizoma Coptidis 165g, Os Sepiae 165g, Bulbus Fritillariae Thunbergii 75g, system Rhizoma Corydalis 75g, Radix Salviae Miltiorrhizae 62g, Cortex Magnoliae Officinalis 42g, Fructus Amomi 38g, Pseudobulbus Bletillae (Rhizoma Bletillae) 85g, Radix Et Rhizoma Rhei 38g.Other is all with embodiment 1.
Embodiment 4
Take by weighing raw material by prescription: Rhizoma Coptidis 165g, Os Sepiae 163g, Bulbus Fritillariae Thunbergii 83g, system Rhizoma Corydalis 83g, Radix Salviae Miltiorrhizae 60g, Cortex Magnoliae Officinalis 40g, Fructus Amomi 40g, Pseudobulbus Bletillae (Rhizoma Bletillae) 80g, Radix Et Rhizoma Rhei 38g.Other is all with embodiment 1.
Discrimination test:
Get medicine of the present invention; Carrying out thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000) test differentiates and measures with the test method of tlc scanning determination; And each item of medicine of the present invention inspection index such as content uniformity, dissolving time limit, moisture content, microbial limit etc. are all tested; The regulation that meets Chinese Pharmacopoeia appendix drug standard, result show that drug quality of the present invention is stable.
Test Example
1, pharmacodynamics test:
Observe medicine of the present invention and whether have antiinflammatory, analgesia, antacid, promotion ulcer surface healing effect, and carry out the pharmacodynamics contrast, for clinical application provides experimental basis with SANJIU WEITAI or aspirin tablet.
(1) xylol causes the influence of mice ear:
Utilize 40 of Kunming male mices, body weight 22-28g is divided into 4 groups at random, 10 every group; Establish distilled water matched group (isometric(al)) respectively, aspirin matched group (0.2g/kg), medicine high dose group 4.0g/kg of the present invention (being equivalent to crude drug 0.7g), low dose group 1.0g/kg (being equivalent to crude drug 0.7g); Press 0.2mL/10g, every day 1 gastric infusion, successive administration 7d, 1h after the last administration; Every mouse right ear evenly is coated with xylene 30 μ L and causes inflammation, puts to death mice after being coated with proinflammatory agent 3h, gets the corresponding position of bilateral auricle; Weighing, is the swelling degree with the difference of left and right auricle weight, calculates inhibitory rate of intumesce; Carry out statistical procedures, the result shows that high and low dose group medicine xylol of the present invention causes mice ear has the obvious suppression effect.See table 1.
(2) to the influence of mice peptic activity of stomach:
Utilize 40 of kunming mices, body weight 22-28g, male and female half and half evenly are divided into 4 groups at random, set up the distilled water matched group separately by an above-mentioned 4. identical method; SANJIU WEITAI matched group and medicine high and low dose group of the present invention, and by identical medication, successive administration 7d; Can't help water 12h in the fasting of 6d mice, 1h after the last administration puts to death animal; Dissect immediately, the method for employing protein pipe test tube is carried out the determination test of peptic activity of stomach, and the result sees table 2.The result shows that medicine of the present invention can obviously suppress peptic activity of stomach.
(3) to the influence of rat acetic acid type gastric ulcer:
Utilize
Wistar40 of rats; Body weight 200 ± 20g evenly is divided into 4 groups at random, is made as the distilled water matched group respectively by an above-mentioned 4. identical method; SANJIU WEITAI matched group and medicine high and low dose group of the present invention; Water 12h is can't help in the experimental animal fasting, anesthesia operation down, and tela submucosa is injected 5% acetic acid 0.1mL in 1cm place, pylorus top.After sewing up stomach wall 2d, every group of experimental animal pressed 1 gastric infusion 0.2mL/10g difference every day, behind the successive administration 14d, under anatomic microscope, observes ulcer level, calculates the ulcer area, and the result sees table 3.The result shows that medicine of the present invention can obviously reduce the gastric ulcer area.
Above-mentioned results of pharmacodynamic test shows that medicine of the present invention has stronger antiinflammatory, analgesia, antacid effect, can obviously suppress peptic activity of stomach, obviously reduces the gastric ulcer area, and the effect that promotes ulcer healing is arranged.
2, toxicology test:
< 1>acute toxicity test:
Measure 1 0.3g of medicine of the present invention (being equivalent to crude drug 0.7g) by regulation, using 0.3%CMC-Na solution to process concentration is 25% suspension, subsequent use.
Test method and result:
Utilize 30 body weight 22-28g of Kunming white mice, the male and female dual-purpose is divided into 2 groups of administration group and matched groups at random, 15 every group.The administration group is pressed 0.4mL/10g body weight gastric infusion with above-mentioned 25% suspension, the upper and lower noon each 1 time, irritate fasting 10h before the stomach, and prohibited water 6 hours; Matched group is irritated the 0.3%CMC-Na solution of stomach with capacity.Observe variations such as the activity of respectively organizing mice after the administration in the 7d, drinking-water, feces, hair color, body weight, the variation of main organs such as the heart of anatomic observation mice, liver,spleen,kidney behind the 7d.The result shows that 2 treated animals are at form, size, the equal no significant difference of smoothness aspects of main organs such as drinking-water, hair color, body weight, feces and the heart, liver,spleen,kidney.2 treated animal body weight are seen table 4.Can not do LD50 because of medicine of the present invention through prerun, can only do a day maximum tolerated dose.The mtd test result is 20g/kg, is 133 times of people's consumption per day.People's consumption per day is 4.5g, and body weight is by 60kg.2 treated animals are not seen death and other abnormal response in the administration 7d.The experimental result prompting, medicine of the present invention does not have tangible acute toxicity effect to white mice.
< 2>chronic toxicity test:
Medicine of the present invention is processed the suspension of pastille 0.20g/mL and 0.005g/mL with the 0.5%CMC-Na aqueous solution.Right
WistarRat, body weight are 100-120g, and the male and female dual-purpose carries out long term toxicity test.3 groups of low dosage and blank groups 60 of said rats evenly being divided at random high dose group and the 1.0g/kg of 4g/kg, 20 every group, male and female half and half.To high and low dose group timing every day gastric infusion once, each 2mL/100g body weight, successive administration 90d; Regularly give 0.5%CMC-Na aqueous solution 2mL/100g body weight every day to the blank group, and the calibrated bolck feedstuff of freely drinking water, freely ingest.During administration 90d; 3 groups of experimental animals are respectively got half the, done that urine, stool routine detect, hematological indices detects and blood parameters detects, and dissection is cored, liver, spleen, brain, lung are done check pathological section; And the residue experimental animal carries out above-mentioned similar detection after 2 weeks of drug withdrawal.The detection check result shows, during administration, the activity of 3 groups of experimental animals, growth, drink water, ingest, feces and body weight gain be all normal, relatively do not have significant difference with the blank group; Medication 90d is carried out the detection of hematological indices and blood parameters 2 weeks respectively with stopping wrapping with straw, and high and low dose administration group and blank group compare, and there was no significant difference between each item index value is all in normal range; 3 groups of experimental animals are made the heart, liver, spleen, brain, lung respectively do check pathological section, all no abnormality seen.Above-mentioned result of the test shows that medicine of the present invention does not see that in to the rat chronic toxicity test cumulative toxicity reaction occurs, and has safety preferably.
3, clinical observation on the therapeutic effect:
Adopt medicine of the present invention to carry out clinical observation on the therapeutic effect, the patient that will meet chronic superficial gastritis Western medicine diagnose standard and Chinese medical discrimination is as the object of observation.Said patient's randomized, double-blind method is divided into treatment organizes 125 examples, matched group 62 examples, clinical data is seen table 5, through statistical procedures, there was no significant difference (P＞0.05), better harmonious between the explanation group, comparability is strong.
Medication: the treatment group is taken medicine of the present invention, and is oral, every day 3 times, each 5; Matched group is taken the ranitidine capsule, and is oral, every day 2 times, each 1.The course of treatment: 2 groups of administration times were for 4 weeks, stop using during the medication antibiotic and other anti-ulcer medicament.
Therapeutic outcome: treatment group cure rate is 67.2%, and obvious effective rate is 26.4%, and total effective rate is 99.2%; The matched group cure rate is 45.2%, and obvious effective rate is 24.2%, and total effective rate is 80.6%.See table 6,7,8.2 groups relatively there were significant differences (P＜0.01); Table 9 is seen in the HP comparison of turning out cloudy after 2 groups of treatments.
Clinical observation on the therapeutic effect is the result show; Drug therapy peptic ulcer of the present invention has curative effect preferably; No matter at ulcer healing; Or all be superior to matched group aspect improving in clinical symptoms, and patient's HP there is the effect of turning out cloudy preferably, do not find the heart, liver, renal function and blood system infringement in the therapeutic process.
Described clinical cure: primary symptom all disappears with time disease, and gastroscope shows the ulcer complete obiteration, and local mild hyperaemia does not have obvious edema; Produce effects: primary symptom and time disease all have clear improvement, or indivedual primary symptom slightly improves, but other symptom all disappears, and gastroscope shows that ulcer disappears basically, still has obvious inflammation; Effectively: primary symptom and time disease all have improvement, or the primary symptom end improves, but inferior disease all disappears, and gastroscope shows that ulcer surface dwindles more than 50%; Invalid: primary symptom, inferior disease all do not have improvement, and gastroscope shows that ulcer surface dwindles not as good as 50%; HP is cloudy to be changeed, with drug withdrawal less than 2 weeks, 2 urease test feminine genders of gastric antrum biopsy are as the criterion, the still negative radical cure that is is rechecked in drug withdrawal 2 thoughtful half a year.Said primary symptom is the glutted discomfort of upper abdomen, irregularities stomachache; Said time disease is belch, pantothenic acid, feels sick, vomits.
Table 1, medicine xylol of the present invention cause the influence of mice ear
Annotate: compare * P＜0.05 * * P＜0.01 with the distilled water group
Annotate: compare * P＜0.05 with the distilled water group
Table 2 medicine of the present invention is to the influence of mice peptic activity of stomach
Annotate: compare * P＜0.05 * * P＜0.01 with the distilled water group
Table 3 medicine of the present invention is to the influence of rat acetic acid type ulcer
Annotate: compare * P＜0.05 * * P＜0.01 with the distilled water group
Table 4 medicine acute toxicity test of the present invention is to the influence of mice body weight
Annotate: compare * P＞0.05 with the distilled water group
Sex, age, the state of an illness are relatively between table 5 liang group
Table 6 liang group treatment curative effect ratio
Annotate: treatment group Qi-stagnation type, blood stasis type compare x with stagnated heat type
2=0.86,17.36 aP＞0.05 bP＜0.05 dP＜0.01, blood stasis type is than Qi-stagnation type x
2=11.13, iP＜0.05 eP＞0.05
Table 7 contrasts curative effect relatively at random
Table 8, different parts peptic ulcer Comparison of therapeutic
The table 9 liang cloudy commentaries on classics contrast of group treatment back HP
Claims (1)
1. medicine of treating gastropathy; It is characterized in that; Prescription is Rhizoma Coptidis 155-165g, Os Sepiae 155-165g, Bulbus Fritillariae Thunbergii 75--85g, system Rhizoma Corydalis 75--85g, Radix Salviae Miltiorrhizae 62-66g, Cortex Magnoliae Officinalis 38-42g, Fructus Amomi 38-42g, Pseudobulbus Bletillae (Rhizoma Bletillae) 75--85g, Radix Et Rhizoma Rhei 38-42g;
Press formula ratio weighting raw materials material, Os Sepiae, the Pseudobulbus Bletillae (Rhizoma Bletillae) pulverized process fine powder, cross medical sieve, subsequent use; Fructus Amomi, Cortex Magnoliae Officinalis are extracted volatile oil, and redistillation makes aqueous solution device collection in addition, and is subsequent use; Adopting water extraction process to process water extraction solution Rhizoma Coptidis, Radix Salviae Miltiorrhizae, system Rhizoma Corydalis, Bulbus Fritillariae Thunbergii, Radix Et Rhizoma Rhei, then merge with above-mentioned subsequent use aqueous solution, is 1.25-1.30 through reducing pressure, being concentrated into relative density; Then with above-mentioned subsequent use fine powder mix homogeneously; Process thick paste, cold drying again, process fine powder, with above-mentioned subsequent use volatile oil mixing; Incapsulate, process capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102627438A CN101926955B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating stomach illness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102627438A CN101926955B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating stomach illness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101926955A CN101926955A (en) | 2010-12-29 |
| CN101926955B true CN101926955B (en) | 2012-06-27 |
Family
ID=43366559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102627438A Expired - Fee Related CN101926955B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating stomach illness |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101926955B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168794A (en) * | 2015-11-03 | 2015-12-23 | 李金友 | Pharmaceutical composition and preparation method, preparations and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183981A (en) * | 1997-12-05 | 1998-06-10 | 刘宜生 | Chinese medicine for gastropathy related to pyloric spiri-bacillus |
| CN1840144A (en) * | 2006-01-18 | 2006-10-04 | 于滨 | Medicine for treating gastric disease |
| CN1943754A (en) * | 2006-10-24 | 2007-04-11 | 提鑫 | A Medicine for treatment of gastrointestinal diseases |
-
2010
- 2010-08-26 CN CN2010102627438A patent/CN101926955B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183981A (en) * | 1997-12-05 | 1998-06-10 | 刘宜生 | Chinese medicine for gastropathy related to pyloric spiri-bacillus |
| CN1840144A (en) * | 2006-01-18 | 2006-10-04 | 于滨 | Medicine for treating gastric disease |
| CN1943754A (en) * | 2006-10-24 | 2007-04-11 | 提鑫 | A Medicine for treatment of gastrointestinal diseases |
Non-Patent Citations (2)
| Title |
|---|
| 孙玉凤等.中医药治疗消化性溃疡研究近况.《中国全科医学杂志》.2000,第3卷(第1期),13-15. * |
| 曾斌芳等.消化性溃疡的中西医研究进展.《新疆中医药》.2006,第24卷(第6期),第53-56. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101926955A (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN104162129B (en) | A kind of Chinese medicine for treating DGP | |
| CN103830674B (en) | One treats lipomatous pharmaceutical composition and preparation method and purposes | |
| CN104623356B (en) | The Chinese medicine for the treatment of helicobacter pylori infections peptic ulcer | |
| CN101926955B (en) | Medicament for treating stomach illness | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN101406556B (en) | Chinese medicine preparation for treating acute prostatitis, prostatic hyperplasia and preparation method thereof | |
| CN101732657A (en) | Medicine composition | |
| CN103933154A (en) | Traditional Chinese medicine composition for treating gout disease and preparation method thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN103948738A (en) | Sore throat relieving anti-inflammatory bird's nest composition and preparation method and application thereof | |
| CN103816265B (en) | A kind ofly be used for the treatment of medicine of having loose bowels and preparation method thereof | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN107519261A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN106074824A (en) | Enhancing immunity and the compositions of prophylactic treatment influenza, preparation technology and purposes | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN101607061A (en) | A kind of drug regimen of protecting gastric mucosa and preparation method thereof | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN105125985A (en) | Chinese and western medicine compound preparation for treating senile chronic bronchitis and preparation method thereof | |
| CN114984179A (en) | Composition for treating or preventing mitiglinide adverse reaction and preparation method and application thereof | |
| CN104367870A (en) | Traditional Chinese medicine composition for preventing and treating hyperglycemia and hyperlipidemia | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20120826 |